Hyattsville, Maryland Clinical Trials

A listing of Hyattsville, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 292 clinical trials
Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer

The purpose of this study is to examine whether setting test groups of cisplatin + irinotecan + Krestin therapy as first-line treatment and chemotherapy (radiotherapy or radiotherapy + chemotherapy also allowed) combined with Krestin as second-line treatment after exacerbation and comparing with historical control or community control is appropriate as …

metastasis
neutrophil count
platelet count
irinotecan
Toho University Sakura Medical Center
 (5.3 away) Contact site
  • 22 views
  • 07 Nov, 2020
  • +13 other locations
Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

Phase II trial of nivolumab in 120 treatment nave patients with ccRCC.

Georgetown University
 (5.8 away) Contact site
  • 82 views
  • 16 Jan, 2021
  • +11 other locations
GE-148-002: A Phase 2 Open-label Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

Background: - GE-148 (18F) is a new drug that is designed to attach to prostate cancer cells. Researchers are interested in combining the drug with a small amount of radioactive material to allow prostate cancer lesions to appear more clearly on imaging scans. Researchers are also interested in determining whether …

National Institutes of Health Clinical Center, 9000 Rockville Pike
 (9.7 away) Contact site
  • 36 views
  • 08 Nov, 2020
  • 1 location
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Background Most people with hairy cell leukemia have a BRAF gene mutation. They can be treated with BRAF inhibitors, drugs that target this mutation. For people who do not have this mutation, BRAF inhibitors are not a treatment option. We found that in hairy cell leukemia, when BRAF is not …

National Institutes of Health Clinical Center
 (9.4 away) Contact site
  • 0 views
  • 18 Jan, 2021
  • 1 location
Encorafenib Plus Binimetinib for People With BRAF V600E Mutated Relapsed/Refractory HCL

Background Hairy cell leukemia (HCL) does not usually respond to chemotherapy. Most people with HCL have a BRAF gene mutation. This can increase the growth of cancer cells. Vemurafenib has been tested to treat these people. However, researchers think a combination of drugs might work better. Objective To test if …

National Institutes of Health Clinical Center
 (9.4 away) Contact site
  • 0 views
  • 17 Jan, 2021
  • 1 location
A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

Background Metastatic urothelial carcinoma is lethal and has no cure. Response rates to current treatments are modest. Researchers want to find new strategies to treat the disease. In this study, they will test a drug called M7824. The drug is a new immunotherapy that blocks the pathways that cancer cells …

metastatic urothelial carcinoma
neuropathy
aptt
antiretroviral
neutrophil count
National Institutes of Health Clinical Center
 (9.4 away) Contact site
  • 0 views
  • 04 Nov, 2020
  • 1 location
A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

Stroke is one of the leading causes of death and major functional disability worldwide. Treatment options for acute stroke are limited with many patients having residual neurologic impairment. The purpose of this study is to evaluate the safety and efficacy of elezanumab and assess change in neurologic function in participants …

Georgetown University Hospital /ID# 216481
 (7.8 away) Contact site
  • 12 views
  • 18 Jan, 2021
  • +30 other locations
Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease

Background Cushing s disease is caused by excess ACTH hormone release by a benign tumor of the pituitary gland. It can lead to decreased quality of life and early death. The current best treatment for Cushing s disease is surgery. If surgery does not work or if the tumor returns, …

adenoma
ACTH
tumor cells
pituitary
free cortisol
National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 21 views
  • 18 Jan, 2021
  • 1 location
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

Background Severe aplastic anemia (SAA) is a rare and serious blood disorder. It causes the immune system to turn against bone marrow cells. Standard treatment for SSA is a combination of 3 drugs (Cyclosporine [CsA], Eltrombopag [EPAG], and horse anti-thymocyte globulin [h-ATG]). Researchers want to see if starting people at …

blood disorder
blood test
reticulocyte count
immunosuppressant
neutrophil count
National Institutes of Health Clinical Center
 (9.4 away) Contact site
  • 1 views
  • 29 Oct, 2020
  • 1 location
Radium-223 in Biochemically Recurrent Prostate Cancer

Background Some men who have been treated for localized prostate cancer with surgery or radiation still show signs of the disease in their blood. This is called biochemically recurrent prostate cancer. Radium-223 is a small molecule. It uses radiation to kill cancer cells and improves survival in advanced prostate cancer. …

National Institutes of Health Clinical Center
 (9.4 away) Contact site
  • 0 views
  • 23 Dec, 2020
  • 1 location